SEL-212

DRUG3 trials

Sponsors

Selecta Biosciences, Inc.

Conditions

Chronic GoutGoutGout ChronicHyperuricemia

Phase 1

Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Levels

CompletedNCT02648269

Selecta Biosciences, Inc.Gout

Start: 2015-12-31End: 2016-12-31Updated: 2017-01-30

Phase 2

Multi-Dose Safety/Pharmacodynamic Study of SEL-212/SEL-037 in Subjects With Symptomatic Gout & Elevated Blood Uric Acid

CompletedNCT02959918

Selecta Biosciences, Inc.Gout Chronic, Hyperuricemia

Start: 2016-10-31End: 2019-01-31Updated: 2022-02-14

A Study to Compare the Efficacy of SEL-212 to KRYSTEXXA® in Gout Participants Refractory to Conventional Therapy

CompletedNCT03905512

Selecta Biosciences, Inc.Chronic Gout

Start: 2019-05-07End: 2020-08-05Updated: 2023-10-17

Related Papers

The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout

Lara D. Veeken2023-07-1418 citations

Phase 2 Dose-Finding Study in Patients with Gout Using SEL-212, a Novel PEGylated Uricase (SEL-037) Combined with Tolerogenic Nanoparticles (SEL-110)

Rheumatology and Therapy2023-04-1721 citations

Tolerogenic nanoparticles mitigate the formation of anti-drug antibodies against pegylated uricase in patients with hyperuricemia.

2022-01-1236 citations